Kuno T, Vasquez N, April-Sanders AK, Swett K, Kizer JR, Thyagarajan B, Talavera GA, Ponce SG, Shook-Sa BE, Penedo FJ, Daviglus ML, Kansal MM, Cai J, Kitzman D, and Rodriguez CJ
Background: Pre-heart failure (pre-HF) is an entity known to progress to symptomatic heart failure (HF)., Objectives: This study aimed to characterize pre-HF prevalence and incidence among Hispanics/Latinos., Methods: The Echo-SOL (Echocardiographic Study of Latinos) assessed cardiac parameters on 1,643 Hispanics/Latinos at baseline and 4.3 years later. Prevalent pre-HF was defined as the presence of any abnormal cardiac parameter (left ventricular [LV] ejection fraction <50%; absolute global longitudinal strain <15%; grade 1 or more diastolic dysfunction; LV mass index >115 g/m 2 for men, >95 g/m 2 for women; or relative wall thickness >0.42). Incident pre-HF was defined among those without pre-HF at baseline. Sampling weights and survey statistics were used., Results: Among this study population (mean age: 56.4 years; 56% female), HF risk factors, including prevalence of hypertension and diabetes, worsened during follow-up. Significant worsening of all cardiac parameters (except LV ejection fraction) was evidenced from baseline to follow-up (all P < 0.01). Overall, the prevalence of pre-HF was 66.7% at baseline and the incidence of pre-HF during follow-up was 66.3%. Prevalent and incident pre-HF were seen more with increasing baseline HF risk factor burden as well as with older age. In addition, increasing the number of HF risk factors increased the risk of prevalence of pre-HF and incidence of pre-HF (adjusted OR: 1.36 [95% CI: 1.16-1.58], and adjusted OR: 1.29 [95% CI: 1.00-1.68], respectively). Prevalent pre-HF was associated with incident clinical HF (HR: 10.9 [95% CI: 2.1-56.3])., Conclusions: Hispanics/Latinos exhibited significant worsening of pre-HF characteristics over time. Prevalence and incidence of pre-HF are high and are associated with increasing HF risk factor burden and with incidence of cardiac events., Competing Interests: Funding Support and Author Disclosures The baseline examination of HCHS/SOL was conducted as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC652237). The following institutes/centers/offices contributed to the HCHS/SOL first funding period through a transfer of funds to the National Heart, Lung, and Blood Institute: National Institute of Deafness and Other Communications Disorders; the National Institute of Dental and Craniofacial Research; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Neurological Disorders and Stroke; and the National Institutes of Health Office of Dietary Supplements. Echo-SOL was supported by grants from the National Heart, Lung, and Blood Institute (R01 HL04199, Epidemiological Determinants of Cardiac Structure and Function among Hispanics; 2R01HL104199, Epidemiologic Determinants of Change in Cardiac Structure and Function among Hispanics: Carlos J. Rodriguez, MD, MPH, principal investigator). Dr Kizer owns stocks in Abbott, Bristol Myers Squibb, Johnson and Johnson, Medtronic, Merck, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)